News | December 04, 2014

Mount Sinai Study Shows Vital Exhaustion May Raise Risk of Cardiovascular Disease

Fatigue, irritability and demoralization can increase risk of first-time event up to 36 percent


December 4, 2014 — Fatigue, increased irritability and feeling demoralized may raise a healthy man or woman’s risk of first-time cardiovascular disease by 36 percent, according to a study led by researchers at Mount Sinai St. Luke’s and Mount Sinai Roosevelt hospitals. Study results were presented on Nov. 17 at the American Heart Association’s Scientific Sessions 2014 in Chicago.

The combination of fatigue, increased irritability and feeling demoralized is medically known as vital exhaustion. In their study, Mount Sinai researchers found that vital exhaustion was associated with a dramatic increase in risk for first-time cardiovascular disease when compared to people not experiencing these three psychological factors.  

“Our study shows vital exhaustion is an important risk factor for the development of cardiovascular disease in otherwise healthy people,” says lead author Randy Cohen, M.D., medical director of the University Medical Practice Associates at Mount Sinai St. Luke's and Mount Sinai Roosevelt. “Loss of vitality thus adds to a growing number of psychosocial risk factors that have now been linked to the development of cardiovascular disease, including anxiety, depression and social isolation.”

Study researchers investigated the relationship between vital exhaustion and first-time heart disease in 11 prospective studies that involved 60,610 people without heart disease. The studies had an average follow-up of 6.5 years.

“The identification of vital exhaustion as a coronary artery disease (CAD) risk factor appears timely,” according to study co-author Alan Rozanski, M.D., Chief of the division of cardiology at Mount Sinai St. Luke’s and Mount Sinai Roosevelt. “As society becomes increasingly fast-paced, there is an increasing tendency for people to overwork while cutting back on sleep, exercise and the rest and relaxation we all need to renew ourselves and prevent the factors that cause vital exhaustion.”

Other study co-authors include: Jincy Thankachen, M.D., and Chirag Bavishi, M.D., of Mount Sinai St. Luke’s and Mount Sinai Roosevelt.

 

For more information: www.mountsinai.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now